Media

Non-Executive Director appointment

13 July 2020

Reading, United Kingdom - ConvaTec Group Plc ("ConvaTec" or “the Company”) announces the appointment of Professor Constantin Coussios FREng as a Non-Executive Director of the Company with effect from 1 September 2020.

Constantin is an internationally recognised key opinion leader in the fields of biomedical engineering, image-guided therapy and drug delivery, and the recipient of the 2017 Silver Medal by the UK’s Royal Academy of Engineering. He is currently the Director of the Institute of Biomedical Engineering, University of Oxford, which is focused on the disciplines of non-invasive therapies, drug delivery, regenerative medicine, medical  imaging, AI in healthcare, neurotechnology and biomaterials . In addition to his role as Director, he also has a proven track record of translating research into technology through academic entrepreneurship. He has served as founder, CEO and CTO of three successful spin-outs, including OrganOx whose normothermic organ preservation technology is in all UK transplant centres, and many European and North-American centres. Between 2014 and 2020, he directed and led the Oxford Centre for Drug Delivery Devices, a cross-disciplinary centre investigating the combination of medical devices and nanotechnology to improve the delivery and efficacy of therapeutics in oncology in collaboration with ten pharmaceutical and medical device companies.


John McAdam, Chairman of ConvaTec, commented:

“I am delighted to welcome Constantin to our Board. He is an eminent academic in the field of biomedical engineering and brings first-hand experience of developing innovative products from concept through development, regulatory approval to commercialisation. His extensive experience and insight shall be invaluable as we focus on innovation to help drive our transformation.”

Constantin is a Statutory Professor of Biomedical Engineering, University of Oxford, and Professorial Fellow of Magdalen College. He is also a non-executive director of OrganOx Limited, OxSonics Limited and OrthoSon Limited; and a Trustee of the Oxford Transplant Foundation.


No other information requires disclosure in accordance with Listing Rule 9.6.13.


This announcement is made in accordance with Listing Rule 9.6.11R(1).

 

Enquiries

Analysts and Investors

ir@convatec.com

Mark Reynolds, Director Investor Relations    

+44 (0)7551 036 625

   

Media

mediarelations@convatec.com

Buchanan: Charles Ryland / Chris Lane / Vicky Hayns      

+44 (0)207 466 5000

 

About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions. The Company is listed on the London Stock Exchange (stock symbol: CTEC) and has established market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. ConvaTec's products provide a range of clinical and economic benefits, including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care.  www.convatecgroup.com.

 

 

Cookies are needed for this website to work optimally. They also help us to know a little bit about how you use our website, which improves the browsing experience.  Cookies on this site are used for traffic measurement and optimisation of page content only. By continuing to browse on this website, you indicate your consent to the use of cookies.  You may block the use of cookies by following the "How to block and avoid cookies" instructions

Learn more about our Cookie policy